Clinical use of tricyclic anticonvulsants in painful neuropathies and bipolar disorders

Epilepsy and Behavior

Volumn 3, Issue 3 SUPPL. 1, 2002, Pages

  Beydoun, Ahmad ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; FLUOXETINE; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; OXCARBAZEPINE; PSYCHOTROPIC AGENT; SODIUM CHANNEL; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VILOXAZINE;

AGED; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIPLOPIA; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MONOTHERAPY; NEUROPATHY; NEUROTRANSMITTER RELEASE; NOTE; PAIN; PAIN ASSESSMENT; POLYNEUROPATHY; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TRIGEMINUS NEURALGIA; VERTIGO;

EID: 0036623734     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-5050(02)00017-3     Document Type: Article

References (28)

1. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsive drug (G32883). Lancet 1963;1:839-40.
2. Campbell FG, Graham JG, Zilka KJ. Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1966;29:265-7.
3. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia: use of side effects. Arch Neurol 1968;19:129-36.
4. Nicol CF. A four-year double-blind study of Tegretol in facial pain. Headache 1969;1:54-7.
5. Farago F. Trigeminal neuralgia: its treatment with two new carbamazepine analogues. Eur Neurol 1987;26:73-83.
6. Zakrzewska JM, Patsalos PN. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1989;52:472-6.
7. Renillard G. Oxcarbazepine and intractable trigerninal neuralgia. Epilepsia 1994;35(Suppl. 3):S28-9.
8. Lindstrom P. The analgesic effect of carbamazepine in trigeminal neuralgia. Pain 1987;28(Suppl. 4):S85.
9. Beydoun A, Schmidt D, D'Souza J. Meta-analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. J Pain 2002;3(Suppl. 1):38.
10. Cummins TR, Waxman SG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J Neurosci 1997;17:3503-14.
11. Devor M. Neuropathic pain and injured nerve peripheral mechanisms. Br Med Bull 1991;47:619-30.
12. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959-64.
13. Attal N, Bouhassira D. Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand Suppl 1999;173:12-24, 48-52.
14. Ichikawa K, Koyama N, Kiguchi S, Kojima M, Yokota T. Inhibitory effect of oxcarbazepine on high-frequency firing in peripheral nerve fibers. Eur J Pharmacol 2001;420:119-22.
15. Stefani A, Pisani A, DeMurtas M, et al. Action of GP 47779, the active metabolite of oxcarbazepine on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995;36:997-1002.
16. Rull JA, Quibrera R, Gonzales-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double-blind crossover trial. Diabetologia 1969;5:215-8.
17. Gomez-Perez FJ, Choza R, Rios JM, et al. Nortriptylinefluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996;27:525-9.
18. Wilton TD. Tegretol in the treatment of diabetic neuropathy. S Afr Med J 1974;48:869-72.
19. Carrazana E, Beydoun A, Kobetz S, Constantine S. An open label, prospective trial of oxcarbazepine in the treatment of painful diabetic neuropathy. J Pain 2002;3(Suppl. 1):38.
20. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985;8:243-50.
21. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berlin) 1979;66:211-7.
22. Lenzi A, Lazzerini F, Grossi E, Massimetti G, Placidi GF. Use of carbamazepine in acute psychosis: a controlled study. J Int Med Res 1986;14:78-84.
23. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987;48:89-93.
24. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153:198-204.
25. Emrich HM, Altmann H, Dose M, von Zerssen D. Therapeutic effects of GABA-ergic drugs in affective disorders: a preliminary report. Pharmacol Biochem Behav 1983;19:369-72.
26. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996;31:198-214.
27. Shukla S, Goldwin CD, Long LE, Miller MG. Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 1984;141:1604-6.
28. Pisani F, Oteri G, Russo M, et al. Double-blind, within-patient study to evaluate the influence of viloxazine on the steady state plasma levels of oxcarbazepine and its metabolites. Epilepsia 1991;32(Suppl. 1):70.